JP2019528677A5 - - Google Patents

Download PDF

Info

Publication number
JP2019528677A5
JP2019528677A5 JP2018566591A JP2018566591A JP2019528677A5 JP 2019528677 A5 JP2019528677 A5 JP 2019528677A5 JP 2018566591 A JP2018566591 A JP 2018566591A JP 2018566591 A JP2018566591 A JP 2018566591A JP 2019528677 A5 JP2019528677 A5 JP 2019528677A5
Authority
JP
Japan
Prior art keywords
antibody
domain
seq
composition
axl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018566591A
Other languages
English (en)
Japanese (ja)
Other versions
JP7071935B2 (ja
JP2019528677A (ja
Filing date
Publication date
Priority claimed from GBGB1610902.7A external-priority patent/GB201610902D0/en
Application filed filed Critical
Publication of JP2019528677A publication Critical patent/JP2019528677A/ja
Publication of JP2019528677A5 publication Critical patent/JP2019528677A5/ja
Application granted granted Critical
Publication of JP7071935B2 publication Critical patent/JP7071935B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018566591A 2016-06-22 2017-06-21 抗Axlアンタゴニスト抗体 Expired - Fee Related JP7071935B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1610902.7 2016-06-22
GBGB1610902.7A GB201610902D0 (en) 2016-06-22 2016-06-22 Anti-Axl Antagonistic Antibodies
PCT/EP2017/065313 WO2017220695A1 (en) 2016-06-22 2017-06-21 Anti-axl antagonistic antibodies

Publications (3)

Publication Number Publication Date
JP2019528677A JP2019528677A (ja) 2019-10-17
JP2019528677A5 true JP2019528677A5 (https=) 2020-07-30
JP7071935B2 JP7071935B2 (ja) 2022-05-19

Family

ID=56895047

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018566591A Expired - Fee Related JP7071935B2 (ja) 2016-06-22 2017-06-21 抗Axlアンタゴニスト抗体

Country Status (10)

Country Link
US (3) US11198734B2 (https=)
EP (1) EP3475305A1 (https=)
JP (1) JP7071935B2 (https=)
KR (1) KR102458196B1 (https=)
CN (2) CN109311997B (https=)
AU (1) AU2017281326A1 (https=)
CA (1) CA3025729A1 (https=)
GB (1) GB201610902D0 (https=)
MX (1) MX2018016096A (https=)
WO (1) WO2017220695A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015366213B2 (en) * 2014-12-18 2021-10-07 Bergenbio Asa Anti-Axl antagonistic antibodies
GB201610902D0 (en) * 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
CN110483639A (zh) * 2018-05-15 2019-11-22 复旦大学 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
NL2024108B1 (en) * 2019-10-26 2021-07-19 Vitroscan B V Methods and apparatus for measuring immune-cell mediated anti-tumoroid responses
US11807688B2 (en) * 2020-02-28 2023-11-07 Les Laboratoires Servier Anti-AXL antibodies and compositions
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
EP4132652A1 (en) 2020-04-08 2023-02-15 BerGenBio ASA Axl inhibitors for antiviral therapy
GB202006072D0 (en) * 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
EP4286406A4 (en) 2021-01-29 2025-07-23 Illimis Therapeutics Inc FUSION MOLECULE WITH NON-INFLAMMATORY PHAGOCYTOSIS-INDUCING ACTIVITY
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
US20250019446A1 (en) * 2021-06-16 2025-01-16 Shanghai Sinobay Biotechnology Co., Ltd. Antibody Targeting Axl Protein and Antigen Binding Fragment Thereof, and Preparation Method Therefor and Application Thereof
WO2022269605A1 (en) * 2021-06-24 2022-12-29 Yeda Research And Development Co. Ltd. Combination therapy for the treatment of cancer comprising an anti-egfr antibody and an axl-inhibitor
CN119968395A (zh) * 2022-08-18 2025-05-09 百进生物科技公司 抗axl抗体、其抗原结合片段及其制备和使用方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
JP5769969B2 (ja) 2007-11-12 2015-08-26 ユー3・ファーマ・ゲーエムベーハー Axl抗体
AU2008321835B2 (en) * 2007-11-15 2014-11-20 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
CA2759836A1 (en) 2009-05-11 2010-11-18 U3 Pharma Gmbh Humanized axl antibodies
KR20120024763A (ko) * 2009-05-15 2012-03-14 추가이 세이야쿠 가부시키가이샤 항axl 항체
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
RU2577986C2 (ru) * 2010-06-18 2016-03-20 Дженентек, Инк. Антитела против axl и способы их применения
CA2839508A1 (en) 2011-06-22 2012-12-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-axl antibodies and uses thereof
ES2677367T3 (es) 2011-06-22 2018-08-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpos anti-Axl y usos de los mismos
EP2589609A1 (en) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
PL2914630T3 (pl) * 2012-11-05 2021-09-06 Pierre Fabre Médicament Nowe białka wiążące antygen i ich zastosowanie jako produktu ukierunkowanego do leczenia raka
US9850297B2 (en) * 2013-03-15 2017-12-26 Amgen Inc. Secreted frizzle-related protein 5 (SFRP5) binding proteins
US20160106861A1 (en) * 2013-04-26 2016-04-21 Spirogen Sarl Axl antibody-drug conjugate and its use for the treatment of cancer
WO2015116753A1 (en) * 2014-01-29 2015-08-06 Dana-Farber Cancer Institute, Inc. Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
GB201410826D0 (en) 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
GB201410825D0 (en) 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
US9986723B2 (en) 2014-10-22 2018-06-05 The Board Of Regents Of The University Of Texas System Screen and use of therapeutics for pancreatic ductal adenocarcinoma
JP6864953B2 (ja) 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Axlに対するヒトモノクローナル抗体
AU2015366213B2 (en) 2014-12-18 2021-10-07 Bergenbio Asa Anti-Axl antagonistic antibodies
GB201610902D0 (en) * 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
US11159088B2 (en) * 2019-06-19 2021-10-26 Appulse Power Inc. Dual path and mode start-up circuit
GB202004189D0 (en) * 2020-03-23 2020-05-06 Bergenbio As Combination therapy

Similar Documents

Publication Publication Date Title
JP2019528677A5 (https=)
JP2018506961A5 (https=)
JP2022177090A5 (https=)
PE20240218A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
HRP20241381T1 (hr) Nova anti-pd-1 protutijela
JP2019107018A5 (https=)
JP2015517300A5 (https=)
JP2017524715A5 (https=)
JP2017535257A5 (https=)
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2017514461A5 (https=)
JP2012254092A5 (https=)
JP2013519364A5 (https=)
JP2015163068A5 (https=)
IL273841B1 (en) Antibodies targeting cd137 and methods of use thereof
AR102698A1 (es) Anticuerpos contra cd73 y sus usos
JP2020504076A5 (https=)
JP2020516305A5 (https=)
AR108034A1 (es) Moléculas de unión a ror1, y métodos de uso de las mismas
JP2016536342A5 (https=)
JP2020514310A5 (https=)
JP2017048240A5 (https=)
JP2018517431A5 (https=)
JP2020501598A5 (https=)
JP2018536393A5 (https=)